ライフサイエンスコーパス: atherosclerotic disease

1 es in shaping the development and outcome of atherosclerotic disease.

2 tified, principally in cases with concurrent atherosclerotic disease.

3 ns are critical given the systemic nature of atherosclerotic disease.

4 for ischemic events resulting from coronary atherosclerotic disease.

5 nts with high-grade symptomatic intracranial atherosclerotic disease.

6 y and prevent the clinical manifestations of atherosclerotic disease.

7 population and in those with already present atherosclerotic disease.

8 ls are inversely related to the incidence of atherosclerotic disease.

9 ls during the development and progression of atherosclerotic disease.

10 mation in mice and are associated with human atherosclerotic disease.

11 oninvasively image experimental and clinical atherosclerotic disease.

12 for endovascular treatment of aneurysmal and atherosclerotic disease.

13 fication of asymptomatic subjects at risk of atherosclerotic disease.

14 as an attractive target for the treatment of atherosclerotic disease.

15 nction represents the first manifestation of atherosclerotic disease.

16 al thrombosis but also in the progression of atherosclerotic disease.

17 a source of bypass conduit for patients with atherosclerotic disease.

18 ciation studies for their relevance in human atherosclerotic disease.

19 m failed to induce regression of established atherosclerotic disease.

20 rrent microbial infections may contribute to atherosclerotic disease.

21 st commonly be the result of degenerative or atherosclerotic disease.

22 revascularization in the setting of diffuse atherosclerotic disease.

23 Noninvasive imaging can detect early atherosclerotic disease.

24 -cell responses influence the progression of atherosclerotic disease.

25 ant therapeutic targets in the management of atherosclerotic disease.

26 and either prevent or reverse the course of atherosclerotic disease.

27 idence that chronic inflammation may promote atherosclerotic disease.

28 hat infection does play an important role in atherosclerotic disease.

29 ithin the arterial wall and are a prelude to atherosclerotic disease.

30 DL are commonly encountered in patients with atherosclerotic disease.

31 evention of coronary heart disease and other atherosclerotic disease.

32 c disease and in the progression of coronary atherosclerotic disease.

33 portant mechanisms by which smoking promotes atherosclerotic disease.

34 cal setting for the investigation of carotid atherosclerotic disease.

35 idely used to treat hypercholesterolemia and atherosclerotic disease.

36 ugments conventional mechanical treatment of atherosclerotic disease.

37 blood lipid levels, a known risk factor for atherosclerotic disease.

38 nd reproducible noninvasive marker of global atherosclerotic disease.

39 he genesis and progression of human coronary atherosclerotic disease.

40 pproaches to the treatment and prevention of atherosclerotic disease.

41 factors is the major strategy for preventing atherosclerotic disease.

42 ns between bacterial or viral infections and atherosclerotic disease.

43 s commonly associated with predisposition to atherosclerotic disease.

44 ns and increased risk of clinically manifest atherosclerotic disease.

45 acute coronary syndromes and progression of atherosclerotic disease.

46 centration of LDL is a major risk factor for atherosclerotic disease.

47 and should greatly enhance basic studies of atherosclerotic disease.

48 macrophage function with relevance for human atherosclerotic disease.

49 mited assessment of changes in the extent of atherosclerotic disease.

50 on lipids may impact the risk of developing atherosclerotic disease.

51 ls have been associated with the presence of atherosclerotic disease.

52 le risk factors associated with intracranial atherosclerotic disease.

53 tic patients have more extensive and diffuse atherosclerotic disease.

54 esting that they may represent less advanced atherosclerotic disease.

55 ne of treatment in patients with established atherosclerotic disease.

56 nt because local flow patterns can influence atherosclerotic disease.

57 g-term secondary prevention in patients with atherosclerotic disease.

58 tic targets to combat the high prevalence of atherosclerotic disease.

59 fits is unclear, particularly with regard to atherosclerotic disease.

60 cal targeting of the CCL2-CCR2 axis in human atherosclerotic disease.

61 TA2-AS1 expression patterns are perturbed in atherosclerotic disease.

62 ions to further explore the role of VSMCs in atherosclerotic disease.

63 aemia and inflammation jointly contribute to atherosclerotic disease.

64 and is associated with an increased risk for atherosclerotic disease.

65 m and thereby influence vascular biology and atherosclerotic disease.

66 tion of restenosis in the presence of severe atherosclerotic disease.

67 fy novel therapeutic approaches for treating atherosclerotic disease.

68 endothelium and potentially contributing to atherosclerotic disease.

69 ent of patients with underlying intracranial atherosclerotic disease.

70 a T-bet-driven humoral response may improve atherosclerotic disease.

71 stabilization or slowing the progression of atherosclerotic disease.

72 mportant roles in lipoprotein metabolism and atherosclerotic disease.

73 is, and is a potential therapeutic target in atherosclerotic disease.

74 l utility in the prophylaxis of inflammatory atherosclerotic disease.

75 ere considered representative of significant atherosclerotic disease.

76 e for symptomatic patients with intracranial atherosclerotic disease.

77 sGC inhibition may provide a novel target in atherosclerotic disease.

78 ychosocial factors in the pathophysiology of atherosclerotic disease.

79 ately benefit individuals with more advanced atherosclerotic disease.

80 ng adults 60 years or older without clinical atherosclerotic disease.

81 -enhanced BB 3-T MR imaging for intracranial atherosclerotic disease.

82 investigation, especially in the context of atherosclerotic disease.

83 treating acute injuries, as well as chronic atherosclerotic disease.

84 n murine models of vascular injury and human atherosclerotic disease.

85 es mellitus is prospectively associated with atherosclerotic disease.

86 temic inflammation, and an increased risk of atherosclerotic disease.

87 stically demonstrates inflammatory damage in atherosclerotic disease.

88 new therapeutic strategies in CKD-associated atherosclerotic disease.

89 eatly benefit the detection and treatment of atherosclerotic disease.

90 were examined for the presence of neointimal atherosclerotic disease.

91 suggested a contribution of periodontitis in atherosclerotic diseases.

92 y heart disease and cerebrovascular or other atherosclerotic diseases.

93 ocioeconomic strata, increasing the risk for atherosclerotic diseases.

94 al risk pathways for PAD compared with other atherosclerotic diseases.

95 age of drugs and diets to reduce the risk of atherosclerotic diseases.

96 al effects of new drugs aiming to cure human atherosclerotic diseases.

97 attractive therapeutic strategy in occlusive atherosclerotic diseases.

98 ajor risk modifiers of neurodegenerative and atherosclerotic diseases(1-3), but their effect on cance

99 9%: 107 [32.2%] vs 42 [20.5%], P < .001) and atherosclerotic disease (296 [82.0%] vs 194 [74.6%], P =

100 e performed in 650 patients with symptomatic atherosclerotic disease (62+/-9 years).

101 CI, 55.4%-55.8%] of patients), have coronary atherosclerotic disease (79.9% [95% CI, 79.7%-80.2%] of

102 is the association between TG levels and non-atherosclerotic diseases across organ systems.

103 ((18)F-fluoride) uptake is a marker of both atherosclerotic disease activity and disease progression

104 Noninvasive measures of coronary atherosclerotic disease activity have the potential to i

105 d coronary vasodilator function, a marker of atherosclerotic disease activity.

106 Peripheral vascular disease (PVD) is an atherosclerotic disease affecting the lower extremities,

107 is associated with clinical and subclinical atherosclerotic disease, although evidence from prospect

108 mbar radiograms, are a marker of subclinical atherosclerotic disease and an independent predictor of

109 as a potentially modifiable risk factor for atherosclerotic disease and aortic stenosis, but there a

110 Lipoprotein(a) (Lp[a]) is associated with atherosclerotic disease and aortic stenosis.

111 nce the risk of adverse events from coronary atherosclerotic disease and available data support our t

112 The degradative SMC phenotype also worsens atherosclerotic disease and could thus be considered as

113 Patients (N = 189) with atherosclerotic disease and either type 2 diabetes melli

114 c and mechanical approaches to patients with atherosclerotic disease and have resulted in improved cl

115 emokines CCL19 and CCL21 are up-regulated in atherosclerotic disease and heart failure, and increased

116 on rates caused by the diffuse nature of the atherosclerotic disease and hypercoagulable state.

117 are effective in slowing the progression of atherosclerotic disease and in reducing the risk of thro

118 ensity lipoprotein in the protection against atherosclerotic disease and in the progression of corona

119 nosis,regardless of symptoms, is a marker of atherosclerotic disease and increased risk for cardiovas

120 In the majority of patients with clinical atherosclerotic disease and isolated hypoalphalipoprotei

121 iplatelet therapy for patients with coronary atherosclerotic disease and might be more effective than

122 us to a focus on controlling the activity of atherosclerotic disease and on modifying the susceptibil

123 itor being developed specifically for use in atherosclerotic disease and poised to be tested formally

124 In patients with symptomatic atherosclerotic disease and relatively mild depressive s

125 In 10 patients with atherosclerotic disease and six patients with symptomati

126 rdiovascular concerns, including the risk of atherosclerotic disease and systemic inflammation, in ex

127 r accounting for an indicator of subclinical atherosclerotic disease and traditional risk factors and

128 er FKN is expressed throughout all stages of atherosclerotic disease and whether it directly contribu

129 th chronic limb-threatening ischaemia due to atherosclerotic disease and who required an infra-poplit

130 erved in patients with CKD but without overt atherosclerotic disease and with few traditional risk fa

131 tions are associated with increasing risk of atherosclerotic disease and with graft stenosis and occl

132 angioplasty, or PTCA) patients with advanced atherosclerotic disease and with procedures performed ac

133 s the relationship between PON1 activity and atherosclerotic diseases and various factors modulating

134 Infections, atherosclerotic disease, and active systemic lupus eryth

135 resolving metabolites are protective against atherosclerotic disease, and ameliorate systemic inflamm

136 demia, extracranial carotid and intracranial atherosclerotic disease, and antithrombotic therapy.

137 actors, progression, coprevalence with other atherosclerotic disease, and association with incident c

138 seases, including allergic rhinitis, sepsis, atherosclerotic disease, and malignancy, in which PAF si

139 sence of atrial fibrillation or intracranial atherosclerotic disease, and time from onset to imaging.

140 Diabetic kidney disease and atherosclerotic disease are major causes of morbidity an

141 a significant approximately 70% decrease in atherosclerotic disease area in double knockout mice on

142 on, would likely lead to the displacement of atherosclerotic disease as the nation's number 1 killer.

143 ated blood lipids and diabetes contribute to atherosclerotic disease, as well as to understand the mo

144 but who did not have either cancer or known atherosclerotic disease at the time of imaging were incl

145 ter myocardial infarction (MI) or those with atherosclerotic disease (ATH), adherence is poor.

146 loci and identify candidate genes for human atherosclerotic disease based on circular chromosome con

147 tid arteries and in differentiating TAK from atherosclerotic disease based on minimal plaque content,

148 This may allow the identification of atherosclerotic disease before it is symptomatic.

149 extremity open revascularization for chronic atherosclerotic disease between 2011 and 2021.

150 unclear whether the high risk is due to high atherosclerotic disease burden or if presence of stenosi

151 onary events mandates a greater focus on the atherosclerotic disease burden rather than on features o

152 cardiovascular calcification correlates with atherosclerotic disease burden.

153 Total IgE (tIgE) is associated with atherosclerotic disease but has limited specificity for

154 Lp(a) (lipoprotein[a]) is a risk marker for atherosclerotic disease, but the underlying mechanisms r

155 Gut microbiota have been implicated in atherosclerotic disease, but their relation with subclin

156 ith hyperlipidemia, hypercholesterolemia and atherosclerotic diseases by reducing cholesterol level a

157 n individuals receiving care for established atherosclerotic disease (coronary artery disease, periph

158 But, until recently, only advanced atherosclerotic disease could be observed.

159 Premature and more aggressive atherosclerotic disease, coupled with an enhanced thromb

160 he developing atheroma and may contribute to atherosclerotic disease development and progression.

161 lipid homeostasis, which effects may impact atherosclerotic disease development.

162 ipoprotein profiling and no prior history of atherosclerotic disease, diabetes, or active lipid-lower

163 Coronary atherosclerotic disease diagnoses also declined after 20

164 The study of atherosclerotic disease during its natural history and a

165 PARTICIPANTS: Visualization of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Preve

166 plasma sphingomyelin to earlier, subclinical atherosclerotic disease has not been reported.

167 and an association of TWAR IgG antibody and atherosclerotic diseases has been observed.

168 diovascular disease manifestations including atherosclerotic disease, heart failure, thromboembolic d

169 een disproportionately higher than for other atherosclerotic diseases, however, recent trends have no

170 Intracranial atherosclerotic disease (IAD) is likely the most common

171 Understanding how symptomatic intracranial atherosclerotic disease (ICAD) evolves with current medi

172 MR) imaging protocol to measure intracranial atherosclerotic disease (ICAD) in a population-based mul

173 nagement options for refractory intracranial atherosclerotic disease (ICAD) involve intracranial sten

174 Intracranial atherosclerotic disease (ICAD) is a common cause of stro

175 Intracranial atherosclerotic disease (ICAD) is an important cause of

176 disease (CSVD), but the role of intracranial atherosclerotic disease (ICAD) remains unknown in the ge

177 vasculitis and risk factors for intracranial atherosclerotic disease (ICAD).

178 eptibility loci for their underlying disease-atherosclerotic disease-identification of candidate gene

179 rable lipid profiles and reduced subclinical atherosclerotic disease in a Pennsylvania Amish populati

180 the BioImage (A Clinical Study of Burden of Atherosclerotic Disease in an At Risk Population) study

181 ioImage Study (A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population) sought

182 d cholesterol efflux capacity and to regress atherosclerotic disease in animal and clinical studies.

183 c nitrate might prove useful in ameliorating atherosclerotic disease in Apolipoprotein (Apo)E knockou

184 tructure, detect the presence of subclinical atherosclerotic disease in high-risk patient subgroups,

185 sis development in mice and a higher risk of atherosclerotic disease in humans.

186 tly required for the development of advanced atherosclerotic disease in mice with a severe defect in

187 The impact of estrogen on atherosclerotic disease in other peripheral arteries is

188 expression and activity are associated with atherosclerotic disease in patients with chronic kidney

189 ce, treatment, and prevention of accelerated atherosclerotic disease in rheumatoid arthritis.

190 ICAS is an imaging marker of established atherosclerotic disease in stroke-free subjects, and inc

191 ore commonly associated with respiratory and atherosclerotic disease in the acute pathophysiology of

192 The odds ratio for atherosclerotic disease in the lower limbs (low ABPI) wa

193 ischemia with rest pain or tissue loss with atherosclerotic disease in the native below-the-knee art

194 ound images were examined from patients with atherosclerotic disease in the proximal left anterior de

195 m failed to induce regression of established atherosclerotic disease in this model.

196 een as extensively studied as other kinds of atherosclerotic disease in this population.

197 ay be a viable method for the attenuation of atherosclerotic disease in vein grafts.

198 inking obesity to increased risk of clinical atherosclerotic diseases in humans.

199 ubstantial improvements in the prevention of atherosclerotic diseases in the UK, the overall burden o

200 n outcomes in heart failure patients without atherosclerotic diseases, indicating the importance of i

201 gs reveal that lipid changes associated with atherosclerotic disease induce decreased production of I

202 s by which cytomegalovirus may contribute to atherosclerotic disease initiation and progression and t

203 Intracranial atherosclerotic disease is a highly prevalent cause of s

204 isms driving sex as a biological variable in atherosclerotic disease is critical to future precision

205 A significant burden of atherosclerotic disease is driven by inflammation.

206 data suggest evolocumab use in patients with atherosclerotic disease is efficacious and safe in patie

207 This increased incidence of atherosclerotic disease is intricately associated with i

208 ns with chronic kidney disease (CKD) because atherosclerotic disease is less prevalent, whereas bleed

209 Carotid atherosclerotic disease is one of the major preventable

210 diac events among young individuals, whereas atherosclerotic disease is primarily responsible for the

211 at endovascular stenting of vertebral artery atherosclerotic disease is safe and effective compared w

212 with AAOCA, concomitant obstructive coronary atherosclerotic disease is the primary determinant of ad

213 ns are effective for secondary prevention of atherosclerotic disease is unknown.

214 nterventional and pharmacological therapy of atherosclerotic disease, it is still the leading cause o

215 to reduce the severity of stenotic coronary atherosclerotic disease, its long-term success is signif

216 s is a well-recognized phenomenon in chronic atherosclerotic disease, its role in sudden coronary dea

217 r ischemic stroke attributed to large-artery atherosclerotic disease (LAD) or small-vessel occlusive

218 that changes in lipid profiles that reflect atherosclerotic disease led to activation of skin murine

219 Pregnancy losses and atherosclerotic disease may be etiologically linked thro

220 od flow (pCBF) in 575 patients with manifest atherosclerotic disease (mean age, 57 +/- 10 years) from

221 33 years +/- 4 [SD]) and five patients with atherosclerotic disease (mean age, 67 years +/- 11.7).

222 human endothelial cells in vitro, in a mouse atherosclerotic disease model, and in human patients.

223 th primary prevention of clinically manifest atherosclerotic disease, must begin in childhood or adol

224 The complexity of atherosclerotic disease necessitates examining the role

225 and selected based on the presence of known atherosclerotic disease (non-HIV atherosclerotic control

226 Framingham risk score (FRS) and had no known atherosclerotic disease (non-HIV FRS-matched controls).

227 The greater severity of atherosclerotic disease observed in patients with CRI ma

228 ho are known to have coronary heart disease, atherosclerotic disease of the aorta or peripheral arter

229 patients with known or clinically suspected atherosclerotic disease of the aortic arch and branch ve

230 Peripheral artery disease is an obstructive, atherosclerotic disease of the lower extremities causing

231 logic and clinical natural history of severe atherosclerotic disease of the thoracic aorta as defined

232 The presence of severe atherosclerotic disease of the thoracic aorta as defined

233 g ATP and ADP are especially associated with atherosclerotic diseases of younger age and smoking.

234 Atherosclerotic disease often involves the intracranial

235 cumab versus placebo in 27 564 patients with atherosclerotic disease on statin therapy followed for a

236 fter intervention may be a marker of diffuse atherosclerotic disease or a consequence of catheter-bas

237 n be made for screening all individuals with atherosclerotic disease or at high risk.

238 In asymptomatic AS patients without known atherosclerotic disease or diabetes mellitus, ELI provid

239 asymptomatic aortic stenosis and no manifest atherosclerotic disease or diabetes mellitus.

240 rentiate persistent obstruction from diffuse atherosclerotic disease or microvascular stunning.

241 of high-risk patients with manifestations of atherosclerotic disease or who have a coronary artery di

242 lar death in adult patients with established atherosclerotic disease or with multiple risk factors fo

243 iring interaction with other risk factors or atherosclerotic disease, or may result from disease rath

244 se drives the neovascularization observed in atherosclerotic disease, our findings identify a possibl

245 its cessation with the incidence of 3 major atherosclerotic diseases (PAD, CHD, and stroke).

246 n for patients with symptomatic intracranial atherosclerotic disease, particularly those with high-gr

247 proteins that influence vascular biology and atherosclerotic disease pathophysiology by regulating li

248 poprotein(a) may be efficacious for multiple atherosclerotic disease phenotypes.

249 els alone do not fully reflect the amount of atherosclerotic disease present.(C) RSNA, 2020See also t

250 as and volumes that occur as a result of the atherosclerotic disease process and during transcatheter

251 by the inhibition of clot formation or even atherosclerotic disease process is one approach.

252 ast CT may become a valuable tool to monitor atherosclerotic disease process noninvasively.

253 elial dysfunction are common features of the atherosclerotic disease process, this unique dual-domain

254 more complete pan-coronary assessment of the atherosclerotic disease process.

255 There is evidence that early detection of atherosclerotic disease processes and subsequent therape

256 idants, and hypertension or other underlying atherosclerotic disease processes.

257 eagents for rapid and noninvasive imaging of atherosclerotic disease progression and plaque vulnerabi

258 ent or monocyte derived, are a key player in atherosclerotic disease progression and regression, and

259 Fap (Fap(-/-)) in Apoe(-/-) mice accelerated atherosclerotic disease progression in both males and fe

260 botic and lipid-lowering agents to attenuate atherosclerotic disease progression in conduits.

261 Atherosclerotic disease progression is determined by loc

262 lance toward a proinflammatory milieu drives atherosclerotic disease progression.

263 ed our understanding of vascular biology and atherosclerotic disease progression.

264 Coronary atherosclerotic disease remains the leading cause of dea

265 n has been cross-sectionally associated with atherosclerotic disease risk factors, but the prospectiv

266 sessed echocardiographic characteristics and atherosclerotic disease risk in 201 survivors of childho

267 icted cardiovascular disease risk (using the atherosclerotic disease risk score) than the rest of the

268 In patients with intracranial atherosclerotic disease, short-term and long-term antico

269 hile platelet MVs (PMVs) are associated with atherosclerotic disease states.

270 th ABCA1 efflux capacity and positively with atherosclerotic disease status.

271 Atherosclerotic diseases such as myocardial infarction,

272 dothelial cells contribute to differences in atherosclerotic disease susceptibility.

273 atients with diabetes are at higher risk for atherosclerotic disease than nondiabetic individuals wit

274 Carotid artery stenosis is atherosclerotic disease that affects extracranial caroti

275 for 37 disease susceptibility loci for human atherosclerotic disease that are of potential interest t

276 29 subjects (aged 40-90 years) with carotid atherosclerotic disease, the 3 intracranial vascular fea

277 in many high-risk patients with established atherosclerotic disease, the elevations in HDL achieved

278 The diffuse nature of lower extremity atherosclerotic disease, the presence of chronic total o

279 inate artery revascularization for occlusive atherosclerotic disease to relieve neurologic (n = 85) a

280 ients >=45 years of age with, or at risk of, atherosclerotic disease undergoing noncardiac surgery to

281 Patients with symptomatic femoro-popliteal atherosclerotic disease undergoing percutaneous translum

282 ts undergo routine screening for subclinical atherosclerotic disease using myocardial perfusion scint

283 LAQUE (Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimo

284 d to men and women, aged 60-69 years, in the Atherosclerotic Disease VAscular functioN and genetiC Ep

285 morphisms (SNPs) in the risk interval in the Atherosclerotic Disease, Vascular Function, and Genetic

286 n some of the decline in angina and coronary atherosclerotic disease visits, it seems that other fact

287 Only obstructive coronary atherosclerotic disease was associated with a higher eve

288 Obstructive coronary atherosclerotic disease was present in 36 patients (21%)

289 asymptomatic aortic stenosis and no manifest atherosclerotic disease were analyzed.

290 yocardial ischemia, and concomitant coronary atherosclerotic disease were collected.

291 ts on a series of biomarkers associated with atherosclerotic disease, whereas levels increased among

292 portunity for early intervention in coronary atherosclerotic disease, which may be augmented by machi

293 men and 4968 women with no prior history of atherosclerotic disease who had baseline Lp(a) determina

294 onth) versus placebo in 27 564 patients with atherosclerotic disease who were on statin therapy, foll

295 us placebo in patients with, or at risk for, atherosclerotic disease who were undergoing noncardiac s

296 heart disease who are found to have coronary atherosclerotic disease with <50% diameter stenosis may

297 ipoprotein cholesterol and lower the risk of atherosclerotic disease (with no clinically meaningful e

298 on outcome for muscle ischemia due to severe atherosclerotic disease, with an overall incidence of 10

299 showed significant associations with 3 major atherosclerotic diseases, with the strongest effect size

300 receiving OAC+ASA did not have a history of atherosclerotic disease, yet 17% had elevated Anticoagul